Fatty acid flux and oxidation are increased by rimonabant in obese women

Metabolism: Clinical and Experimental

Volumn 61, Issue 9, 2012, Pages 1220-1223

  Backhouse, Katharine ^a   Sarac, Ivana ^a   Shojaee Moradie, Fariba ^a   Stolinski, Michael ^a   Robertson, M Denise ^a   Frost, Gary S ^b   Bell, Jimmy D ^b   Thomas, E Louise ^b   Wright, John ^a   Russell Jones, David ^a   Umpleby, A Margot ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

FCR; fractional clearance rate; IHCL; IMCL; intrahepatocellular lipid; intramyocellular lipid; MCR; metabolic clearance rate; Ox; oxidation rate; production rate; Ra; REE; resting energy expenditure; secretion rate; SR; TEE; TG; total energy expenditure; triglyceride; very low density lipoprotein.; VLDL

Indexed keywords

FATTY ACID; PALMITIC ACID; RIMONABANT; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; DRUG ACTIVITY; ENERGY BALANCE; ENERGY EXPENDITURE; FATTY ACID METABOLISM; FEMALE; HUMAN; INSULIN SENSITIVITY; LIPOLYSIS; LOW CALORY DIET; MAJOR CLINICAL STUDY; OBESITY; OXIDATION KINETICS; POSTMENOPAUSE; PRIORITY JOURNAL; WEIGHT REDUCTION;

ADIPONECTIN; AGED; BREATH TESTS; CHOLESTEROL; DIET, REDUCING; ENERGY INTAKE; ENERGY METABOLISM; FATTY ACIDS; FEMALE; GREAT BRITAIN; HUMANS; INSULIN RESISTANCE; LEPTIN; LIPOLYSIS; LIPOPROTEINS, VLDL; MIDDLE AGED; OBESITY; OXIDATION-REDUCTION; PALMITIC ACIDS; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; TRIGLYCERIDES; WEIGHT LOSS;

EID: 84865509985     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2012.02.012     Document Type: Article

References (17)

1. V. Di Marzo, and I. Matias Endocannabinoid control of food intake and energy balance Nat Neurosci 8 2005 585 589
2. S. Engeli, J. Bohnke, and M. Feldpausch Activation of the peripheral endocannabinoid system in human obesity Diabetes 54 2005 2838 2843
3. D. Osei-Hyiaman, M. DePetrillo, and P. Pacher Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity J Clin Invest 115 2005 1298 1305
4. I. Matias, M.P. Gonthier, and P. Orlando Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia J Clin Endocrinol Metab 91 2006 3171 3180
5. C. Ravinet Trillou, C. Delgorge, and C. Menet CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity Int J Obes Relat Metab Disord 284 2004 640 648
6. O. Jbilo, C. Ravinet-Trillou, and M. Arnone The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance Faseb J 19 2005 1567 1569
7. Y.L. Liu, I.P. Connoley, and C.A. Wilson Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice Int J Obes 29 2005 183 187
8. J.P. Despres, A. Golay, and L. Sjostrom Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia N Engl J Med 353 2005 2121 2134
9. L.F. Van Gaal, A.M. Rissanen, and A.J. Scheen Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 365 2005 1389 1397
10. F.X. Pi-Sunyer, L.J. Aronne, and H.M. Heshmati RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial JAMA 295 2006 761 775
11. M. Flamment, N. Gueguen, and C. Wetterwald Effects of the cannabinoid CB1 antagonist, rimonabant, on hepatic mitochondrial function in rats fed a high fat diet Am J Physiol Endocrinol Metab 297 2009 E1162 1170
12. D. Osei-Hyiaman, J. Liu, and L. Zhou Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice J Clin Invest 118 2008 3160 3169
13. J. Tam, V.K. Vemuri, and J. Liu Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity J Clin Invest 120 2010 2953 2966
14. V. di marzo The endocannabinoid system in obesity and type 2 diabetes Diabetologia 51 2008 1356 1367
15. E.J. Ishac, L. Jiang, and K.D. Lake Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves Br J Pharmacol 118 1996 2023 2028
16. B. Mittendorfer, B.W. Patterson, and S. Klein Effect of weight loss on VLDL-triglyceride and apoB-100 kinetics in women with abdominal obesity Am J Physiol Endocrinol Metab 284 2003 E549 556
17. A.M. Strack, S. Nicolich, and T. Faidley Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss Metabolism 2011 10.1016/j.metabol.2011.09.002